iHealthScreen develops an AI-driven, integrated retinal imaging system designed for screening age-related macular degeneration (AMD), diabetic retinopathy (DR) and glaucoma. The company highlights that its systems can be used outside hospitals and incorporated into primary care facilities to improve access and reduce screening costs. iHealthScreen has received CE certification as well as Australian and UAE health approvals for AMD, DR and glaucoma screening. It reports existing customers and international traction with contracts in the U.S., E.U., Bangladesh and the UAE and a collaboration with Global Victoria in Australia. The company holds one U.S. patent for late AMD prediction, has one patent pending and four provisional patent applications, and is working to secure additional research grants. On the financing side, iHealthScreen has raised seed capital and received NIH funding to support development and research.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2023